Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector.
The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver).
The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer.
"synopsis" may belong to another edition of this title.
Steven Gray is a Senior Clinical Scientist and Adjunct Assistant Professor in the Thoracic Oncology Research Group, Trinity Centre for Health Sciences at St. James's Hospital, Dublin, Ireland.
Epigenetic Cancer Therapy articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. The book covers the basic background of the epigenome, aberrant epigenetics and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in lung, breast, prostate, liver, and other specific cancers. It also encompasses both large scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventive strategies.
Epigenetics represents a unique potential therapeutic vista that is emerging at a critical time, and as it has been suggested that a 1% reduction in cancer deaths would be worth $500 billion to the USA, almost 2.5 times what it spends annually on this disease. Uniting issues central to a translational audience, Epigenetic Cancer Therapy is indispensable reading for cancer specialists and oncologists, clinicians, researchers, academics, students, government bodies, and decision makers in the healthcare sector.
"About this title" may belong to another edition of this title.
Seller: Chiron Media, Wallingford, United Kingdom
Hardcover. Condition: New. Seller Inventory # 6666-ELS-9780128002063
Seller: Revaluation Books, Exeter, United Kingdom
Hardcover. Condition: Brand New. 1st edition. 748 pages. 9.40x7.70x1.70 inches. In Stock. Seller Inventory # __0128002069
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector. The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver). The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. 748 pp. Englisch. Seller Inventory # 9780128002063
Seller: AHA-BUCH GmbH, Einbeck, Germany
Buch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector. The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver). The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Seller Inventory # 9780128002063